Cover Image

Role of Cell‐Cycle Proliferation Test, Triple Hit Phenotype, and TMPRSS2‐ERG Expression to Evaluate the Risk of Progression in Prostate Cancer Patients Under Active Surveillance

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Marco Oderda, Giulia Orlando, Giorgio Calleris, Giulia Capella, Luisa Delsedime, Eleonora Duregon, Paola Francia di Celle, Donatella Pacchioni, Ian Marc Bonapace, Zaibunnisa Zaibunnisa, Daniele D'Agate, Gabriele Montefusco, Claudia Filippini, Mauro Papotti, Paolo Gontero
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	The Prostate
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging‐Invisible Prostate Cancers: A Matched‐Pair Analysis
by: Marco Oderda, et al.
Published: (2024)

Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro
by: Megan H. Check, et al.
Published: (2025)

ERG and PTEN Role on Active Surveillance for Low‐Risk Prostate Cancer in the Multiparametric MRI Era
by: Marco Aurelio Watanabe Yorioka, et al.
Published: (2024)

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer
by: Anna‐Lena Lemster, et al.
Published: (2025)

Surveillance Versus Treatment for Favorable Intermediate‐Risk Prostate Cancer and Mortality‐Risk
by: Mutlay Sayan, et al.
Published: (2026)

Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms
by: Charly Bâcle, et al.
Published: (2025)

Association of Area of Deprivation Index With Active Surveillance (AS) Utilization and Adherence to as Guidelines: Results From a Contemporary North American Cohort
by: Alessandro Bertini, et al.
Published: (2025)

Prognostic value of circulating tumor cells in oligorecurrent hormone‐sensitive prostate cancer patients undergoing stereotactic body radiation therapy
by: Fabio Matrone, et al.
Published: (2024)

A Pilot Study of 18 F‐rhPSMA‐7.3‐PET/MRI to Reduce Mischaracterization of Active Surveillance and Focal Therapy Candidates With Occult Higher Risk Disease
by: Ridwan Alam, et al.
Published: (2026)

Are NCCN and EAU Active Surveillance Criteria Reliable in Patients With ISUP Grade‐2 Intermediate‐Risk Prostate Cancer? A Novel Model Integrating MRI to Predict Adverse Pathology
by: Serdar Madendere, et al.
Published: (2025)

Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance
by: Taku Naiki, et al.
Published: (2025)

Robot‐Assisted Salvage Prostatectomy: External Validation of the EAU Selection Criteria and Identification of the Optimal Candidate: A Junior ERUS/YAU Collaborative Study
by: Mike Wenzel, et al.
Published: (2025)

Other‐cause mortality in incidental prostate cancer
by: Francesco Di Bello, et al.
Published: (2024)

Diagnostic Performance of the Novel Biomarker S2,3PSA Density for Prostate Biopsy Optimization in Prostate Imaging Reporting and Data System 3–5 Lesions
by: Takanori Tokunaga, et al.
Published: (2025)

Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
by: Yuto Ono, et al.
Published: (2025)

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
by: Cevat İlteriş Kıkılı, et al.
Published: (2026)

Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
by: Hyun‐Kyung Ko, et al.
Published: (2025)

Cover Image: Volume 86 Issue 7
by: Amod Sharma, et al.
Published: (2026)

External validation of the Memorial Sloan Kettering Cancer Center preoperative nomogram predicting lymph node invasion in a cohort of high‐grade prostate cancer patients
by: Nawar Touma, et al.
Published: (2024)

Modern predictors and management of incidental prostate cancer at holmium enucleation of prostate
by: Eric V. Li, et al.
Published: (2024)

Discovering the Prostate: Notes on History and Historiography
by: Diederik F. Janssen
Published: (2025)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
by: Toshifumi Takahashi, et al.
Published: (2024)

USPSTF Recommendation Against PSA Screening vs. Stage and Cancer‐Specific Mortality in Localized Prostate Cancer
by: Fabian Falkenbach, et al.
Published: (2025)

Insights and Limitations in Evaluating Testosterone Recovery With LHRH Antagonists and Agonists
by: Satı Coşkun Yazgan, et al.
Published: (2026)

Real‐World Comparison of Triplet Versus Doublet Therapy in Japanese Patients With High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: A Propensity‐Weighted Analysis From the YUSHIMA Registry and Exploratory Bayesian Evidence Synthesis
by: Yosuke Yasuda, et al.
Published: (2026)

Utility of the PROSTest, a Novel Blood‐Based Molecular Assay, Versus PSA for Prostate Cancer Stratification and Detection of Disease
by: Mark Kidd, et al.
Published: (2025)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
by: Meryam Losee, et al.
Published: (2025)

Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
by: Hirotaka Nagasaka, et al.
Published: (2024)

Individualized Precision Prostate Biopsy Strategy for Patients With PI‐RADS Score 2: A Retrospective Multicenter Study
by: Zhiyao Xu, et al.
Published: (2025)

Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region
by: Angel Borque‐Fernando, et al.
Published: (2025)

Confirmation of BIK and SAMHD1 as Prostate Cancer Susceptibility Genes
by: Christian P. Pavlovich, et al.
Published: (2025)

Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization
by: Pedro Ivo C. Ravizzini, et al.
Published: (2026)

Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer
by: Umang Swami, et al.
Published: (2024)

Correction to “[Efficacy of Serenoa repens Extract Combined With Alfuzosin Versus Alfuzosin Alone in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Multicenter Randomized Study ( The Prostate , 2025). https://doi.org/10.1002/pros.70071]”
Published: (2026)

Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort
by: Victor Yu, et al.
Published: (2025)

Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy
by: Shintaro Narita, et al.
Published: (2024)

Spatial Distribution of Prostate Cancer Missed by MRI‐Targeted Biopsy, Effect of a Perilesional Template, and Restaging in a Radical Prostatectomy Cohort
by: Ruth Himmelsbach, et al.
Published: (2026)

Letter to the Editor Regarding “Challenging the Evolving Nomenclature of Ultrasound‐Guided Transperineal Prostate Biopsy: A Call for Standardization”
by: Eriz Özden, et al.
Published: (2026)

Ten‐year functional and oncological outcomes of a prospective randomized controlled trial comparing laparoscopic versus robot‐assisted radical prostatectomy
by: Enrico Checcucci, et al.
Published: (2024)

Issue Information
Published: (2024)